|
United States Patent 5,420,128
|
| United States Patent |
5,420,128 |
| Kiyokawa, et. al. |
May 30, 1995 |
17.beta.-substituted 4-aza-5.alpha.-androstan-3-one derivatives
| Inventors: |
Panzeri; Achille (Merate, IT); Nesi; Marcella (Milan, IT); di
Salle; Enrico (Milan, IT). |
| Assignee: |
Farmitalia Carlo Erba S.R.L. (Milan, IT). |
| Appl. No.: |
098,935 |
| Filed: |
Jul. 29, 1993 |
Foreign Application Priority Data
| Jul. 31, 1992 [GB] |
9216329 |
| Intl. Cl.: |
A61K 31/58 |
| U.S. Cl.: |
514/284; 546/ 77; 544/125; 544/361 |
| Field of Search: |
514/284; 546/77 |
References Cited
U.S. Patent Documents
Foreign Patent Documents
| 0155096 |
Sept., 1985 |
EP |
|
| 0200859 |
Nov., 1986 |
EP |
|
| 0271220 |
Jun., 1988 |
EP |
|
| 0484094 |
May, 1992 |
EP |
|
Other References
- Liang et al. J. Steroid Biochem. vol. 19 No. 1 pp. 385-390 (1983).
Lamb et al. The
Prostate vol. 21 pp. 15-34 (1992).
Stinson, Chem. and Eng. News, Jun. 29, 1992 pp. 7 and 8.
Journal of Medicinal Chemistry, vol. 29, No. 11, Nov. 1, 1986, Gary H. Rasmusson, et
al., "Azasteroids: Structure-Activity Relationships for Inhibition of
5-.alpha.-Reductase and of Androgen Receptor Binding", pp. 2298-2315.
Journal of Medicinal Chemistry, vol. 27, No. 12, Dec. 1984, Gary H. Rasmusson, et al.,
"Azasteroids as Inhibitors of Rat Prostatic 5-.alpha.-Reductase", pp. 1690-1701.
Primary Examiner: Daus; Donald G.
Attorney, Agent or Firm: Oblon, Spivak, McClelland, Maier & Neustadt
Abstract
A compound of formula (I): ##STR1## wherein R is a hydrogen atom or a C(1) -C(4)
alkyl group;
- A is a single bond or a straight or branched C(1) -C(6) alkylene chain;
- R(1) is a hydrogen atom or a C(1) -C(6) alkyl group;
- R(2) is a C(1) -C(6) alkyl group, a C(5) -C(7)
cycloalkyl or a C(6) -C(10) cycloalkylalkyl group, aryl or a C(7) -C(10)
arylalkyl group, or a C(6) -C(10) heterocyclylalkyl group;
- R(3) is hydrogen, a C(1) -C(4) alkyl group or an aryl or a C(7)
-C(10) arylalkyl group;
- Z is a C(1) -C(6) alkyl group, an --OR(5) group wherein R(5)
is a C(1) -C(6) alkyl group, ##STR2## group wherein each of R(6) and
R(7) is hydrogen, C(1) -C(6) alkyl, C(5) -C(7)
cycloalkyl, phenyl or R(6) and R(7) taken together with the nitrogen to
which they are linked form a pentatomic or hexatomic saturated heteromonocyclic ring; and
the symbol represents a single or a double bond, is a testosterone 68 5.alpha.-reductase
inhibitor and is therapeutically useful in benign prostatic hyperplasia, prostatic and
breast cancers, seborrhoea, female hirsutism and male pattern baldness.
4 Claims, No Drawings
content2 |
|